Investment Risk Analysis: ROTAPHARM LIMITED

1. Risk Rating: HIGH

The rating reflects extreme balance sheet volatility, a thin equity buffer (shareholders' funds represent only ~10% of total assets), and overwhelming concentration in unexplained "other debtors" that constitute 90% of total assets. The company's financial trajectory shows significant instability, with total assets swinging between £293K and £2M over recent years without clear commercial justification for a single-employee pharmaceutical operation.

2. Key Concerns

Concern 1: Debtors Composition and Concentration Risk

The 2024 balance sheet shows £765,843 in "other debtors" with zero trade debtors. This single line item represents approximately 90% of total assets. The nature of these "other debtors" is not disclosed in the notes, and the dramatic shift from 2023 (where trade debtors were £400,891 and other debtors were £201,767) raises serious questions about what this balance represents and its recoverability. For a pharmaceutical wholesale business, the absence of trade debtors is highly unusual.

Concern 2: Extreme Balance Sheet Volatility

Total assets have fluctuated dramatically: - 2019: £1.99M → 2021: £293K → 2022: £1.11M → 2023: £641K → 2024: £852K

Shareholders' funds have ranged from £30K (2022) to £652K (2017). This level of volatility is inconsistent with stable pharmaceutical trading operations and suggests either significant related-party transactions, restructuring activity, or an unsustainable business model. The 2021 nadir saw net assets at £242K before the balance sheet inflated again.

Concern 3: Liability Structure and Creditor Shift

There has been a dramatic reclassification between years: - Trade creditors moved from £0 (2023) to £754,855 (2024) - Other creditors moved from £572,648 (2023) to £5,298 (2024)

This near-total swap in creditor composition within 12 months, combined with the debtors shift, suggests substantial related-party or intercompany movements rather than genuine trading activity.

3. Positive Indicators

• Audited Accounts with Unqualified Opinion: The financial statements have been audited by Thomas Quinn, with an unqualified opinion stating they give a "true and fair view." This provides some external validation, though the small companies regime limits disclosure requirements.

• Filing Compliance: Accounts and confirmation statements are filed on time with no overdue items. The company has maintained an active status since 2005, demonstrating 20 years of corporate continuity.

• Positive Equity and Cash Improvement: Shareholders' funds increased from £60K to £84K year-on-year, and cash improved from £38K to £86K. The company is technically solvent with net current assets of £84K.

4. Due Diligence Notes